The FDA has delayed a decision on Biogen Idec's hemophilia B therapy Alprolix.
The Obama administration says Medicare drug discounts have saved U.S. recipients $8.9 billion so far in prescription drug costs. Of course, the more they save, the less drugmakers earn, since they are the ones having to pony up the discounts, which the Obama administration is looking to make even larger.
Now that the FDA has fired off a strongly worded rebuke of its Personal Genome Service, 23andMe is standing by the accuracy of its un-approved test, promising to work with regulators but giving no indication that it'll stop selling its sole product.
A morning-after contraceptive pill sold in Europe may not work in women who weigh more than 176 pounds, regulators there said, triggering an FDA review of Teva Pharmaceutical's PlanB One-Step product and its generic versions.
Thermo Fisher is plodding along with its blockbuster agreement to trade $13.6 billion for competitor Life Technologies, picking up European Commission approval on the condition that it sheds a few business units.
Ten years after BTG weathered a tempest as the FDA erected a barrier to its new treatment for varicose veins, the British biotech company has finally gained U.S. approval for its product and confidently predicts it can register peak sales of $500 million a year.
Hospira's long-troubled infusion pump business is dealing with another recall, earning the FDA's most severe warning over a device malfunction the agency said can lead to serious injury and death.
The FDA did a hard about-face today on GlaxoSmithKline's diabetes drug Avandia, deciding that the drug presents no more heart risk than the most commonly used Type 2 diabetes drugs and withdrawing the label warnings and other restrictions.
Johnson & Johnson and its partner Medivir won a green light from the FDA late on Friday to begin marketing their hepatitis C drug simeprevir, which will now be sold as Olysio.
Boston Scientific won FDA approval for yet another next-generation drug-eluting coronary stent system and has immediately ramped up its marketing machine to pursue new sales.